<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04543578</url>
  </required_header>
  <id_info>
    <org_study_id>DIGESTIVO CHN-VBP</org_study_id>
    <nct_id>NCT04543578</nct_id>
  </id_info>
  <brief_title>Evaluation of a Protocol for Multidisciplinary Management of Acute Cholecystitis.</brief_title>
  <official_title>Evaluation of the Applicability and Effectiveness of a Protocol for the Multidisciplinary Management of Acute Cholecystitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundacion Miguel Servet</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundacion Miguel Servet</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acute cholecystitis is a complex disease and its management is sometimes controversial. Two&#xD;
      main factors contribute to its complexity: the patient's surgical risk and the possibility of&#xD;
      concomitant choledocholithiasis. The design of a multidisciplinary protocol between the&#xD;
      services of Gastroenterology and Surgery aims to harmonize its management and to adapt it to&#xD;
      the most recent guidelines. As it concerns more than one department, it is crucial to analyze&#xD;
      its compliance and effectiveness.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Adult patients attending the emergency department and diagnosed with acute cholecystitis will&#xD;
      be asked to participate. Those considered not suitable for surgery will be admitted in a&#xD;
      medical department and assigned to conservative treatment or cholecystostomy, according to&#xD;
      their acute cholecystitis severity. In patients suitable for surgery, risk of concomitant&#xD;
      choledocholithiasis will be assessed and patients will be assigned to low risk or&#xD;
      intermediate-high risk. The latter will be admitted in a medical department, and&#xD;
      choledocholithiasis will be ruled out and treated if present. The former will be offered&#xD;
      cholecystectomy or cholecystostomy according to their surgical risk and acute cholecystitis&#xD;
      severity. A flowchart with extended information is attached.&#xD;
&#xD;
      PRIMARY OBJECTIVES&#xD;
&#xD;
      â€¢ To harmonize the management of acute cholecystitis with a multidisciplinary protocol based&#xD;
      on the most recent guidelines.&#xD;
&#xD;
      SECONDARY OBJECTIVES&#xD;
&#xD;
        -  To analyze the compliance with this protocol.&#xD;
&#xD;
        -  To evaluate the validity of the criteria used in the decision-making process.&#xD;
&#xD;
        -  To assess the morbidity and mortality of different groups of patients according to the&#xD;
           selected treatment, severity of cholecystitis and baseline characteristics of the&#xD;
           patient.&#xD;
&#xD;
        -  To estimate the resource use in each group of patients.&#xD;
&#xD;
        -  To compare current data with a previous period.&#xD;
&#xD;
        -  To adapt and modify the protocol according the study results. INCLUSION CRITERIA&#xD;
&#xD;
        -  Patients aged 18 or older who agree to participate (an informed consent signature is&#xD;
           required)&#xD;
&#xD;
        -  Patients attended in the emergency department of our hospital and diagnosed with acute&#xD;
           cholecystitis according to the Tokyo criteria.&#xD;
&#xD;
      EXCLUSION CRITERIA&#xD;
&#xD;
        -  Patients under 18 years or patients who refuse to participate in the study&#xD;
&#xD;
        -  Patients diagnosed with acute cholangitis during admission for other causes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2020</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Inclusion rate</measure>
    <time_frame>During inclusion period</time_frame>
    <description>Rate of patients with AC diagnosis registered in the study</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Protocol compliance</measure>
    <time_frame>During inclusion period</time_frame>
    <description>Rate of patients with complete protocol compliance</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Morbidity in the different subtypes of patients</measure>
    <time_frame>three months after hospital discharge</time_frame>
    <description>length of hospital stay, need for unplanned readmissions, recurrent cholecystitis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mortality in the different subtypes of patients</measure>
    <time_frame>three months after hospital discharge</time_frame>
    <description>90-day disease-specific mortality</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Protocol compliance failure</measure>
    <time_frame>every 3 months throughout study completion (up to 1 year)</time_frame>
    <description>Identify causes of protocol compliance failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the technical success</measure>
    <time_frame>During inclusion period (up to 1 year)</time_frame>
    <description>Evaluate clinical success and adverse events of the different treatments.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the accuracy in the diagnosis</measure>
    <time_frame>three months after hospital discharge or after ERCP</time_frame>
    <description>Evaluate the accuracy of Magnetic Resonance Cholangiopancreatography (MRCP) and EUS in the diagnosis of concomitant choledocholithiasis</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Acute Cholecystitis</condition>
  <arm_group>
    <arm_group_label>Patients unfit for Surgery with mild-moderate acute cholecyst</arm_group_label>
    <description>Conservative treatment (antibiotics, etc). EUS-guided gallbladder drainage will be considered in recurrent acute cholecystitis and in patients with no improvement in 48-72h after admission.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients unfit for Surgery with severe acute cholecystitis</arm_group_label>
    <description>Percutaneous cholecystostomy or Endoscopic Ultrasound (EUS)-guided cholecystostomy (the latter is not 24/7 available). Palliative care may also be considered in patients with very serious conditions and low life expectancy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients suitable for Surgery with high and intermediate risk</arm_group_label>
    <description>Admission in Gastroenterology Department. antibiotic treatment. Close follow-up of posible AC complications. Once choledocholithiasis is solved or ruled our, the patient will be considered for same-admission cholecystectomy or programmed cholecystectomy.&#xD;
High risk: Endoscopic Retrograde Cholangiopancreatography (ERCP) will be performed.&#xD;
Intermediate risk: EUS or Magnetic Resonance Cholangiopancreatography prior to consider ERCP.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients suitable for Surgery with low risk</arm_group_label>
    <description>Admission in Surgery Department. According to the AC severity:&#xD;
Mild-moderate AC: check de ASA/Charlson comorbidity index.&#xD;
ASA I-II/Charlson &lt;6: laparoscopic cholecystectomy&#xD;
ASA &gt; =III/Charlson &gt;=6: close follow-up 24-48h. Consider laparoscopic cholecystostomy (if no improvement is achieved)&#xD;
Severe AC: consider Intensive Care Unit admission. Percutaneous cholecystectomy.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients attended in the emergency department of CHN and diagnosed with acute&#xD;
        cholecystitis.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients aged 18 or older who agree to participate (an informed consent signature is&#xD;
             required)&#xD;
&#xD;
          -  Patients attended in the emergency department of our hospital and diagnosed with acute&#xD;
             cholecystitis according to the Tokyo criteria.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients under 18 years or patients who refuse to participate in the study&#xD;
&#xD;
          -  Patients diagnosed with acute cholangitis during admission for other causes.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Federico Bolado Concejo, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Complejo Hospitalario de Navarra</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Federico Bolado Concejo, MD, PhD</last_name>
    <phone>0034848422025</phone>
    <email>fboladoc@cfnavarra.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ruth Garcia Rey, MS</last_name>
    <phone>0034848422163</phone>
    <email>ruth.garcia.rey@navarra.es</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Complejo Hospitalario de Navarra</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Federico Bolado Concejo, MD, PhD</last_name>
      <phone>848422025</phone>
      <email>fboladoc@cfnavarra.es</email>
    </contact>
    <contact_backup>
      <last_name>Ruth GarcÃ­a Rey, MSc</last_name>
      <phone>848422163</phone>
      <email>ruth.garcia.rey@navarra.es</email>
    </contact_backup>
    <investigator>
      <last_name>Federico Bolado Concejo, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marian Casi Villaroya, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lucas BlÃ¡zquez Lautre, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pablo Sanchez Acedo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cristina SaldaÃ±a DueÃ±as, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Belen GonzÃ¡lez de la Higuera Carnicer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Erika Borobio Aguilar, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Amaia Arrubla Gamboa, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bruno Camarero Triana, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Yokoe M, Hata J, Takada T, Strasberg SM, Asbun HJ, Wakabayashi G, Kozaka K, Endo I, Deziel DJ, Miura F, Okamoto K, Hwang TL, Huang WS, Ker CG, Chen MF, Han HS, Yoon YS, Choi IS, Yoon DS, Noguchi Y, Shikata S, Ukai T, Higuchi R, Gabata T, Mori Y, Iwashita Y, Hibi T, Jagannath P, Jonas E, Liau KH, Dervenis C, Gouma DJ, Cherqui D, Belli G, Garden OJ, GimÃ©nez ME, de SantibaÃ±es E, Suzuki K, Umezawa A, Supe AN, Pitt HA, Singh H, Chan ACW, Lau WY, Teoh AYB, Honda G, Sugioka A, Asai K, Gomi H, Itoi T, Kiriyama S, Yoshida M, Mayumi T, Matsumura N, Tokumura H, Kitano S, Hirata K, Inui K, Sumiyama Y, Yamamoto M. Tokyo Guidelines 2018: diagnostic criteria and severity grading of acute cholecystitis (with videos). J Hepatobiliary Pancreat Sci. 2018 Jan;25(1):41-54. doi: 10.1002/jhbp.515. Epub 2018 Jan 9. Review.</citation>
    <PMID>29032636</PMID>
  </reference>
  <reference>
    <citation>Ansaloni L, Pisano M, Coccolini F, Peitzmann AB, Fingerhut A, Catena F, Agresta F, Allegri A, Bailey I, Balogh ZJ, Bendinelli C, Biffl W, Bonavina L, Borzellino G, Brunetti F, Burlew CC, Camapanelli G, Campanile FC, Ceresoli M, Chiara O, Civil I, Coimbra R, De Moya M, Di Saverio S, Fraga GP, Gupta S, Kashuk J, Kelly MD, Koka V, Jeekel H, Latifi R, Leppaniemi A, Maier RV, Marzi I, Moore F, Piazzalunga D, Sakakushev B, Sartelli M, Scalea T, Stahel PF, Taviloglu K, Tugnoli G, Uraneus S, Velmahos GC, Wani I, Weber DG, Viale P, Sugrue M, Ivatury R, Kluger Y, Gurusamy KS, Moore EE. 2016 WSES guidelines on acute calculous cholecystitis. World J Emerg Surg. 2016 Jun 14;11:25. doi: 10.1186/s13017-016-0082-5. eCollection 2016. Review. Erratum in: World J Emerg Surg. 2016 Nov 4;11:52.</citation>
    <PMID>27307785</PMID>
  </reference>
  <reference>
    <citation>Chisholm PR, Patel AH, Law RJ, Schulman AR, Bedi AO, Kwon RS, Wamsteker EJ, Anderson MA, Elta GH, Govani SM, Prabhu A. Preoperative predictors of choledocholithiasis in patients presenting with acute calculous cholecystitis. Gastrointest Endosc. 2019 May;89(5):977-983.e2. doi: 10.1016/j.gie.2018.11.017. Epub 2018 Nov 19.</citation>
    <PMID>30465770</PMID>
  </reference>
  <reference>
    <citation>ASGE Standards of Practice Committee, Maple JT, Ben-Menachem T, Anderson MA, Appalaneni V, Banerjee S, Cash BD, Fisher L, Harrison ME, Fanelli RD, Fukami N, Ikenberry SO, Jain R, Khan K, Krinsky ML, Strohmeyer L, Dominitz JA. The role of endoscopy in the evaluation of suspected choledocholithiasis. Gastrointest Endosc. 2010 Jan;71(1):1-9. doi: 10.1016/j.gie.2009.09.041.</citation>
    <PMID>20105473</PMID>
  </reference>
  <reference>
    <citation>ASGE Standards of Practice Committee, Buxbaum JL, Abbas Fehmi SM, Sultan S, Fishman DS, Qumseya BJ, Cortessis VK, Schilperoort H, Kysh L, Matsuoka L, Yachimski P, Agrawal D, Gurudu SR, Jamil LH, Jue TL, Khashab MA, Law JK, Lee JK, Naveed M, Sawhney MS, Thosani N, Yang J, Wani SB. ASGE guideline on the role of endoscopy in the evaluation and management of choledocholithiasis. Gastrointest Endosc. 2019 Jun;89(6):1075-1105.e15. doi: 10.1016/j.gie.2018.10.001. Epub 2019 Apr 9.</citation>
    <PMID>30979521</PMID>
  </reference>
  <reference>
    <citation>Manes G, Paspatis G, Aabakken L, Anderloni A, Arvanitakis M, Ah-Soune P, Barthet M, Domagk D, Dumonceau JM, Gigot JF, Hritz I, Karamanolis G, Laghi A, Mariani A, Paraskeva K, Pohl J, Ponchon T, Swahn F, Ter Steege RWF, Tringali A, Vezakis A, Williams EJ, van Hooft JE. Endoscopic management of common bile duct stones: European Society of Gastrointestinal Endoscopy (ESGE) guideline. Endoscopy. 2019 May;51(5):472-491. doi: 10.1055/a-0862-0346. Epub 2019 Apr 3.</citation>
    <PMID>30943551</PMID>
  </reference>
  <reference>
    <citation>Luk SW, Irani S, Krishnamoorthi R, Wong Lau JY, Wai Ng EK, Teoh AY. Endoscopic ultrasound-guided gallbladder drainage versus percutaneous cholecystostomy for high risk surgical patients with acute cholecystitis: a systematic review and meta-analysis. Endoscopy. 2019 Aug;51(8):722-732. doi: 10.1055/a-0929-6603. Epub 2019 Jun 25.</citation>
    <PMID>31238375</PMID>
  </reference>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>September 2, 2020</study_first_submitted>
  <study_first_submitted_qc>September 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 10, 2020</study_first_posted>
  <last_update_submitted>December 10, 2020</last_update_submitted>
  <last_update_submitted_qc>December 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute cholecystitis</keyword>
  <keyword>EUS-guided cholecystostomy</keyword>
  <keyword>Percutaneous cholecystostomy</keyword>
  <keyword>Laparoscopic cholecystectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholecystitis</mesh_term>
    <mesh_term>Acalculous Cholecystitis</mesh_term>
    <mesh_term>Cholecystitis, Acute</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>September 28, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/78/NCT04543578/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

